Caredx Stock News

CareDx will Directly Support Organ Transplant Patients with Specialty Prescription Services CareDx will Directly Support Organ Transplant Patients with Specialty Prescription Services

Although CareDx (CDNA) recently received inquiries from the DOJ and SEC, the longer-term investment case remains intact. CDNA has only begun to scratch the surface on its total market opportunity and

Shares of CareDx, Inc (NASDAQ:CDNA) have been assigned a consensus recommendation of Buy from the eight research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have issued a buy recommendation and one has issued []

OAKLAND, Calif.--(BUSINESS WIRE)---- $CDNA #CDNA--Gibbs Law Group is investigating potential legal claims on behalf of CareDx investors.

1,000 Patient ALAMO Study will Evaluate the Clinical Utility of LungCare to Detect Transplant Infection and Rejection 1,000 Patient ALAMO Study will Evaluate the Clinical Utility of LungCare to Detect Transplant Infection and Rejection

CareDx, Inc (NASDAQ:CDNA) Director Michael Goldberg sold 500 shares of the firms stock in a transaction dated Thursday, December 9th. The stock was sold at an average price of $45.41, for a total transaction of $22,705.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the []

Perkins Capital Management Inc. reduced its holdings in CareDx, Inc (NASDAQ:CDNA) by 41.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 60,442 shares of the companys stock after selling 42,200 shares during the period. CareDx makes up 2.4% []

CareDx (NASDAQ:CDNA) and Genetron (NASDAQ:GTH) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings. Earnings and Valuation This table compares CareDx and Genetrons gross revenue, earnings per share and valuation. Gross Revenue []

Acushnet Holdings, CareDx, Lululemon and Chewy highlighted as Zacks Bull and Bear of the Day

This stock has beaten the Zacks Consensus Estimate in each of the last four quarters but it has fallen to the lowest Zacks Rank.

Overview of Global Human Leukocyte Antigen (HLA) Typing for Transplant Market: Human Leukocyte Antigen (HLA) Typing for Transplant is a professional and wide-ranging report containing market parameters about the Healthcare industry. The report pinpoints on the leading Market competitors with explaining

This stock has beaten the Zacks Consensus Estimate in each of the last four quarters but it has fallen to the lowest Zacks Rank.

CareDx, Inc (NASDAQ:CDNA) CFO Ankur Dhingra purchased 5,000 shares of the companys stock in a transaction that occurred on Wednesday, November 24th. The shares were purchased at an average cost of $42.34 per share, with a total value of $211,700.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which []

It doesn't take a lot to own a piece of these rapidly growing healthcare businesses.

Equities research analysts expect that CareDx, Inc (NASDAQ:CDNA) will announce earnings per share of $0.02 for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for CareDxs earnings, with the highest EPS estimate coming in at $0.03 and the lowest estimate coming in at $0.01. CareDx reported earnings per share of $0.08 []